Propanc Biopharma, Inc. (PPCB)
2025-03-31 | 2024-12-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Unrealized foreign currency translation gain (loss) | -27,311 | 321,230 | -98,943 | |
| Total other comprehensive income (loss) | -27,311 | 321,230 | -98,943 | |
| Research and development | 54,097 | 54,388 | 61,714 | |
| Occupancy expenses - related party | 6,469 | 5,401 | 8,317 | |
| Administration expenses | 53,068,147 | 153,593 | 220,759 | |
| Total operating expenses | 53,128,713 | 213,382 | 290,790 | |
| Loss from operations | -53,128,713 | -213,382 | -290,790 | |
| Interest income | 1 | - | 1 | |
| Interest expense | 104,042 | 118,943 | 86,230 | |
| Gain (loss) on extinguishment of debt, net | -809,954 | -18,759 | -11,319 | |
| Foreign currency transaction gain (loss) | -12,486 | -84,121 | 8,423 | |
| Change in fair value of derivative liabilities | 47,119 | 13,581 | 52,787 | |
| Derivative expense | 59,271 | 8,559 | 27,182 | |
| Total other income (expense), net | -938,633 | -216,801 | -63,520 | |
| Loss before taxes | -54,067,346 | -430,183 | -354,310 | |
| Net loss | -54,067,346 | -430,183 | -354,310 | |
| Net loss available to common stockholders | -54,067,346 | -430,183 | -354,310 | |
| Total comprehensive loss | -54,094,657 | -108,953 | -453,253 | |
| Basic eps | -12.5 | -32.23 | - | |
| Diluted eps | -12.5 | -32.23 | - | |
| Basic average shares | 4,325,994 | 13,347 | 590,937,498 | |
| Diluted average shares | 4,325,994 | 13,347 | 590,937,498 | |